Gene alterations affecting TP53 are proved to be a strong prognostic factor for NSCLC [5], and recent reports indicate a role for these mutations in predicting EGFR-mutated NSCLC patients responsiveness to TKIs. Here, TP53 is linked to non-small cell lung carcinoma.